Moreover, Miyoshi and colleagues[63] suggest using intratumoral levels of CYP3A4/7 mRNA as predictors of response to antineoplastic drugs such as docetaxel in the treatment of breast cancer; and further involvement of the CYP3A family in drug clearance may have subsequent effects on patient prognosis[28]. The gene discussed is CYP3A4; the disease is breast cancer.